191018-57-2 Usage
Uses
Used in Pharmaceutical Industry:
2-METHYL-4-OXO-4-(3',4'-DIFLUOROPHENYL)BUTYRIC ACID is used as an anti-inflammatory agent for the treatment of various inflammatory conditions such as arthritis and musculoskeletal disorders. Its mechanism of action involves the inhibition of COX enzymes, thereby reducing the levels of prostaglandins that mediate pain and inflammation.
Used in Research Applications:
In the scientific community, 2-METHYL-4-OXO-4-(3',4'-DIFLUOROPHENYL)BUTYRIC ACID is used as a research tool to study the role of COX enzymes and prostaglandins in inflammation and pain pathways. It aids in understanding the underlying mechanisms of action for NSAIDs and their potential therapeutic applications.
Used in Cancer Research:
2-METHYL-4-OXO-4-(3',4'-DIFLUOROPHENYL)BUTYRIC ACID is used as a potential anti-cancer agent in research settings. Studies are exploring its effects on various types of cancer, given its ability to modulate pathways involved in tumor growth and progression.
Used in Antioxidant Studies:
As a compound with potential anti-oxidant properties, 2-METHYL-4-OXO-4-(3',4'-DIFLUOROPHENYL)BUTYRIC ACID is utilized in research to investigate its role in combating oxidative stress and its implications for various diseases and conditions where oxidative stress plays a significant role.
Check Digit Verification of cas no
The CAS Registry Mumber 191018-57-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,9,1,0,1 and 8 respectively; the second part has 2 digits, 5 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 191018-57:
(8*1)+(7*9)+(6*1)+(5*0)+(4*1)+(3*8)+(2*5)+(1*7)=122
122 % 10 = 2
So 191018-57-2 is a valid CAS Registry Number.
191018-57-2Relevant academic research and scientific papers
4-phenyl-4-oxo-butanoic acid derivatives with kynurenine-3-hydroxylase inhibiting activity
-
, (2008/06/13)
4-phenyl-4-oxo-butanoic acid derivatives for use in the treatment of the human or animal body by therepy; particularly as kynurenine-3-hydroxylase inhibitors, in the prevention and/or treatment of a neurodegenerative disease wherein the inhibition of such an enyzme is needed. The present invention further comprises a selected class of the above mentioned 4-phenyl-4-oxo-butanoic acid derivatives, their pharmaceutically acceptable salts, a process for their preparation and pharmaceutical compositions containing them.
